Serplulimab Injection.

Slulizumab
Anti-tumor innovative drug
Indications
MSI-H solid tumors, squamous non-small cell lung cancer
Slulizumab is an innovative anti-tumor drug, a PD-1 (programmed death receptor 1) monoclonal antibody independently developed by Henlius. [1]
In March 2022, the drug was approved for marketing in China for the first time, with the first indication being the treatment of microsatellite high instability (MSI-H) solid tumors. On November 1, 2022, Henlius announced that Slulizumab was approved for a second indication, which is the combination of carboplatin and nab-paclitaxel for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer that cannot be surgically resected. [1]v